Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

Because RNAs are so central to our biology, they are also drivers of a wide array of diseases. Defects in how RNA is produced ...